Organic & Biomolecular **Chemistry**

Accepted Manuscript

This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](http://www.rsc.org/Publishing/Journals/guidelines/AuthorGuidelines/JournalPolicy/accepted_manuscripts.asp).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](http://www.rsc.org/help/termsconditions.asp) and the Ethical quidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

www.rsc.org/obc

Organic & Biomolecular Chesmitry RSCPublishing

ARTICLE

Cite this: DOI: 10.1039/x0xx00000x

Received 00th January 2012, Accepted 00th January 2012

DOI: 10.1039/x0xx00000x

www.rsc.org/

Unique Photophysical Properties of 9-Styryl-1,2 dihydropyrrolo[3,4-*β***]indolizin-3-one and Their Efficient Synthesis via Direct C-H Activation†**

Eun Joung Choi^a and Seung Bum Park*,a,b

Styryl Seoul-Fluor (SF) skeleton was rationally designed by introducing olefin unit at the C-9 of 1,2-dihydropyrrolo[3,4-*β*]indolizin-3-one via regioselective direct C–H activation. We synthesized a series of styryl SF analogues, maintaining unique photophysical properties that can be systematically controlled by electronic characters of the substituents, with an average bathochromic shift of 39 nm in emission maxima.

Introduction

Fluorescent organic molecules have received significant attention as research tools in biological science and clinical diagnosis due to their excellent selectivity, sensitivity, large linear range of analysis, and ease of handling.¹ Despite the high demand for fluorescent materials, only a limited number of chemical families are routinely used since the development of novel fluorophore scaffolds is still challenging.² To obtain the desired photophysical properties, recent studies have been focused on the structural modification of existing fluorophores. The following strategies have been used to study the structurephotophysical property relationship (SPPR) on a certain fluorophore: 1) introduction of electron-donating or withdrawing groups, 3 2) rigidification of rotatable moieties, $4\overline{3}$) replacement of a carbon or oxygen atom with a heteroatom,⁵ 4) extension of the π-conjugated system,⁶ and 5) fusion of a heteroaromatic ring onto fluorophores.⁷

Among these approaches, extension of the π -conjugated system via the insertion of an additional double bond into the organic fluorophores has been widely used to modulate their photophysical properties. In the case of cyanine dye, the addition of an olefin unit in the linker region between two indoles results in a bathochromic shift of 100 nm in its emission maxima (Fig. 1). 8 Further extension of the π conjugation with an additional olefin unit led to another 100-nm red shift to the near infrared region. An identical strategy was applied to BODIPY TR (left) to achieve a bathochromic shift of 32 nm in BODIPY 630/650 (right) via olefin insertion (Fig. 1).⁹ In the case of the coumarin-derived dye-sensitized solar cell (DSSC), an addition of olefin unit between the cyanoacrylic acid and the coumarin core produced two-fold increase in absorption bandwidth in the visible region as well as a red shift in absorption maxima, which led to a significant improvement in the light-harvesting ability of DSSC dyes as photosensitizers.¹⁰

Fig. 1 Influence of an additional olefin on the emission maxima for fluorescent molecules and absorption threshold/maxima of DSSC dye.

We reported the discovery of 1*H*-pyrrolo-[3,4-*β*]indolizin-3-one, a full-color-tunable fluorophore, named as Seoul-Fluor (SF) .¹¹ We also demonstrated the predictability of its emission maximum through a systematic correlation study of the electronic properties of substituents at the C-7 and C-9 positions of SF.¹² Application of SF as a platform for fluorescent bioprobes allowed the real-time monitoring of pH,¹³ VHR phosphatase activity,¹⁴ cellular lipid droplet,¹⁵ etc. In addition to emission wavelength, we systematically controlled the fluorescence quantum yields through the regulation of photoinduced electron transfer (PeT) within the core skeletons. Development of a facile synthetic method to produce SF using direct C–H activation allowed access to a broad substrate scope for various SF analogues.¹⁶ Overall strategy about the discovery of SF, fundamental understanding of its structure-photophysical property relationship, and its subsequent biological application was recently reported as an account. 17

Fig. 2 Original and proposed synthetic routes for the olefin insertion at the C-9 position of Seoul-Fluor.

With a novel fluorescent core in hand, we envisioned further diversification of Seoul-Fluor's photophysical properties via olefin insertion. Through the calculation of atomic coefficients of highest occupied molecular orbital (HOMO) and lowest occupied molecular orbital (LUMO) (Fig. S1), we determined the C-9 position as the ideal site for substituents to maximize the systematic perturbation of their photophysical properties. Previous observation also indicated that substituents with different electronic properties at the C-9 position caused dramatic changes in the emission wavelength.¹² Therefore, we aimed to explore a new version of Seoul-Fluor, namely styryl SF, via olefin insertion at the C-9 position. We envisioned that the extension of the π -conjugated system would lead to a diversification of their photophysical properties. As shown in Fig. 2 (upper), insertion of an olefin between the γ-lactam-embedded indolizine core and aryl ring might be achieved through intramolecular 1,3-dipolar cycloaddition of β,γ,δ,ε-unsaturated amide with a pendant azomethine ylide. Unfortunately, we failed to obtain the olefin-inserted SF product even after extensive trials, which is probably due to the low reactivity of the dipolarophile, β,γ-unsaturated carbon, in the presence of δ,εunsaturated styryl group acting as an electron sink. To overcome this synthetic challenge, we aimed to develop an efficient synthetic route for the olefin insertion in Seoul-Fluor framework. As shown in Fig. 2 (lower), disconnection of the styryl group at the C-9 position allows construction via a modular strategy for efficient diversification at the late-stage of the synthesis. Therefore, we applied this new synthetic route to introduce styryl units into the preformed indolizine core using a regioselective Heck-type coupling of substituted styrenes via direct C–H activation at the C-9 position of 1*H*-pyrrolo-[3,4-*β*]indolizin-3 one.¹⁶

Results and discussion

1,3-Dipolar cycloaddition of the terminal acetylene as a robust synthesis of the indolizine-based core.

We initiated our studies by synthesizing the γ-lactam-embedded indolizines **4a**–**c**, the key substrates for direct C–H activation. As shown in Fig. 3, secondary amine **2** was prepared by nucleophilic substitution of propargyl amine with Boc-protected 3-aminopropyl bromide **1**. The resulting amine **2** was acylated with 2-bromoacetyl

Fig. 3 Synthesis of **4a**–**c**. Reagents and conditions: (a) propargyl amine, DIPEA, ACN, 60°C ; (b) bromoacetyl bromide, TEA, DCM, -78 °C; then 4-substituted pyridine, DCM, 60 °C; (c) DBU, toluene/DCM $(1:1, v/v)$; (d) Ag₂O was added during the cycloaddition reaction.

bromide, followed by the treatment of substituted pyridines to afford the pyridinium salts **3**. The resulting pyridinium intermediate **3** was subjected, without further purification, to intramolecular $[3+2]$ cycloaddition with the pendant terminal acetylene. The azomethine ylide was generated *in-situ* upon treatment with 1,8-diazabicyclo [5.4.0]undec-7-ene (DBU). Unlike the alkenyl dipolarophiles in our original procedure,^{11,12} intramolecular 1,3-dipolar cycloaddition of alkynyl dipolarophiles allows spontaneous oxidative aromatizaton of the resulting tricyclic adduct to afford γ-lactam-embedded indolizines **4a**–**c** in good to moderate yields, without the need for additional oxidants such as 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ). In the case of **4c**, containing an electron-donating methyl group as the R² substituent, we observed an improved yield for the 1,3-dipolar cycloaddition upon activation of the alkyne in the presence of silver oxide.16,18

Regioselective Pd-mediated C–H activation for introduction of styryl moiety to indolizine core.

We then screened different reaction conditions for palladiummediated C–H activation of the C-9 position using **4a** as a model substrate. As shown in Table 1, styrene was employed as the model olefin, for simplicity. The initial reaction was not catalytic in

Table 1 Reaction optimization for direct C–H alkenylation of **4a**.

^aDetermined by HPLC analysis using 7-hydroxycoumarin as an internal standard.

Organic & Biomolecular Chemistry Accepted Manuscript& Biomolecular Chemistry Accepted Manuscri proanic

palladium and the desired product was formed in low yield in the presence of a Pd (II) catalyst (Table 1, Entries 1–3). Excellent regioselectivity was observed for the functionalization of the C-9 position over the C-6 position of the indolizine core. In contrast to the Pd(II) catalysts used, Pd(0) catalysts including Pd(PPh₃)4 and Pd2(dba)³ provided none of the desired product **5** (data not shown). Based on this observation, we hypothesized that regeneration of Pd(II) from Pd(0) through the addition of a stoichiometric oxidant would result in increasing catalytic turnover. With this initial result in hand, we optimized the reaction conditions for $4a$ using $Pd(OAc)_{2}$ and screened various oxidants, solvents, and temperatures. Among the oxidants screened, AgOAc was the most effective in increasing the catalytic turnover rate for this transformation (Table 1, Entries 4–7). After a solvent screening (Table 1, Entries 7–12), we finalized the optimal conditions for site-specific alkenylation via direct C–H activation in the presence of 10mol% Pd(OAc)² and stoichiometric AgOAc under the elevated temperature. Further optimization indicated that the addition of 10% acetic acid as a co-solvent resulted in an excellent yield (Table 1, Entry 12). This result is presumably due to the role of the acetate ion as a base/ligand, which is in accordance with a concerted metalation deprotonation (CMD) pathway.¹⁹

Table 2 Electronic effects of substituents on the isolated yield and photophysical properties.^a

^aSee the Supporting Information for detailed experimental procedures. ^bRecrystalization yield. ^cLongest absorption wavelength maxima. ^dExcited at the longest absorption wavelength maxima. ^eAbsolute fluorescence quantum yield. ^fMolar extinction coefficient. ^gObtained via the reduction of **6**. ${}^{\text{h}}$ Cu(OAc)₂ was used as the oxidant

Examination of the substrate scope for this transformation was undertaken by reacting **4a** with various substituted styrenes containing both electron-withdrawing $(NO₂, F₅, CF₃, Br)$ and electron-donating functional groups (Me, OMe, NH2). As shown in Table 2, all styryl SF analogues (**5**–**12**) were obtained in moderate to excellent yields. No regioisomers were observed for any of the styrene derivatives, further confirming the excellent regioselectivity of this direct C–H activation. In addition to acetyl indolizine **4a**, the coupling efficiency of indolizine cores bearing both an electron-withdrawing methyl ester

(**4b**) and an electron-donating methyl group (**4c**) were examined. Reactivity of **4b** was comparable to **4a** and afforded olefinated products with various substituents (**13**–**15**) in moderate yields. Methyl indolizine **4c**, however, produced significantly diminished yields for the Heck-type coupling product (**16**–**18**), which is consistent with our previous observations.¹⁶ In the case of **17**, copper acetate was a more effective oxidant than silver acetate. It is worth mentioning that the regioselective olefination of **4a**–**c** by this method allows the late-stage functionalization, which ensures the efficient construction of styryl SF analogues with excellent diversity.

General bathochromic shift in emission wavelength of styryl Seoul-Fluor analogs.

Having established a new synthetic method to access the styryl SF analogues, we immediately turned our attention to the analysis of their photophysical properties including absorption/emission maxima ($λ_{abs}/λ_{em}$), quantum yield (Φ_F), and molar extinction coefficient (ε). As previously proposed, extension of the π -conjugated system via the insertion of an additional double bond in Seoul-Fluor might lead to the perturbation of their photophysical properties. Compared to the original SF series, styryl SF analogues showed a decrease in quantum yields, potentially due to the increased non-radiative energy loss associated with additional rotatable bonds at the C-9 position (Table 3). However, the quantum yield is elaborately controlled by the electronic characters of the C-9 substituents, consistent with our previous report.¹⁶

Table 3. Direct comparison of molecular structures and photophysical properties of Seoul-Fluor and styryl Seoul-Fluor analogues. a

^aPhotophysical properties of all samples were measured in dichloromethane. ^bLongest absorption wavelength maxima. ^cExcited at the longest absorption wavelength maxima. ^dAbsolute fluorescence quantum yield.

A bathochromic shift in emission wavelength was observed for all styryl SF analogues when compared to the original SF series. Increasing the electron-donating ability of the R_1 substituent in styryl SF's from F⁵ (**7**) to NH² (**12**) produced a bathochromic shift in emission wavelength from 527 nm to 588 nm. In accordance with our hypothesis, we observed a general bathochromic shift in emission wavelength through the olefin insertion to Seoul-Fluor. Emission wavelength of styryl SF with NO² (**6**) shows significantly red-shifted emission wavelength (618 nm) compared to other styryl SF analogues.

Fig. 4 Correlation plot between emission wavelength and Hammett constant (σ_p) of R₁ substituents in original SF and styryl SF analogues.

This phenomenon was presumably due to the characteristics of nitro group via n $\rightarrow \pi^*$ transition and the detailed influence of nitro group on the photophysical properties of styryl SF will be reported in due course. As shown in Table 3, the emission wavelength of styryl SF analogues showed an average of 39 nm of bathochromic shift compared to that of original SFs. The emission wavelength shift produced by olefin insertion in Seoul-Fluor is not as drastic as that observed in the cyanine case. This might be caused by the distortion of bond angles between the indolizine ring and styryl group leading to the reduction of efficiency in the π conjugation system.

Since it is reasonable to infer that the electronic perturbation produced by the styryl substituents influences the photophysical properties of the styryl SF analogues, we plotted the emission wavelength versus the Hammett constant (σ_p) , which represents the electronic properties of the R_1 substituents (Fig. 4).²⁰ Both SF and styryl SF analogues showed a positive correlation with emission wavelength and an inverse correlation with quantum yields (Fig. S2) in proportion to the electron donating ability of the R¹ group. Therefore, the new styryl SFs are expected to serve as a discovery platform for novel bioprobes with longer emission wavelengths, while maintaining the advantageous tunability of SFs in emission wavelength and quantum yields.

Conclusions

We have developed a novel palladium-catalyzed regioselective olefination of 1,2-dihydropyrrolo[3,4-*β*]indolizin-3-one, namely Seoul-Fluor, via direct C–H activation to overcome limitations with the existing synthetic process for styryl Seoul-Fluor analogues. With this new synthetic route in hand, we could efficiently access a diverse collection of styryl SF analogues with excellent substrate generality via the late-stage diversification. In agreement with our hypothesis, we observed the general bathochromic shifts of emission wavelength maxima in styryl SF analogues (39 nm in average), compared to that of SF analogues. This result confirms that the extension of π -conjugated system by olefin insertion between indolizine core and C-9 substituents in Seoul-Fluor leads to the perturbation of its photophysical properties. This palladium-mediated site-specific olefination via direct C–H activation is a powerful and atom-economic method for the olefination of heterocyclic cores, which allows for the efficient diversification of Seoul-Fluor at the late stage of the synthesis.

Experimental

General Methods

Organic & Biomolecular Chemistry Accepted Manuscripttetramethylsilane (TMS) standard. Multiplicity was indicated as follows: s (singlet); d (doublet); t (triplet); q (quartet); m (multiplet); ganic & Biomolecular Chemistry Accepted Manuscri dd (doublet of doublet); dt (doublet of triplet); br s (broad singlet), etc. High resolution mass analyses were performed at the Mass Spectrometry Laboratory of Seoul National University by direct injection on a JEOL JMS AX505WA spectrometer using fast atom bombardment (FAB) method. Absorbance of final fluorescence compounds was measured by UV-VIS spectrophotometer UV-

1650PC (Shimatzu, Japan). Excitation and Emission maxima were measured by Cary Eclipse Fluorescence spectrophotometer (Varian Assoc., Palo Alto, USA). Absolute quantum yield was measured by absolute PL quantum yield measurement system QE-1000 (OTSUKA Electronics). *In silico* calculations were performed using the Materials Studio® 4.2 program (Accelrys Software Inc.) A generalized gradient approximation (GAA) for the exchange correlation function of Perdew, Burke, and Ernzerhof (PBE) was used with the double numerical basis set with polarization (DNP) as implemented in DMol3. Internal standard analysis for checking yield of crude reaction was performed on SHIMADZU HPLC equipped with a reverse phase column (XDB C18, 5 μ m, 4.6 \times 150 mm). Samples were analyzed starting with 5% ACN in H2O (0.1% TFA) for 5 min after injected 10 μL of sample and solvent was changed from 5% ACN in H₂O $(0.1\%$ TFA) to 100% ACN $(0.1\%$ TFA) for 30 min with 1.0 mL/min flow. Absorbance was detected by 365 nm. **Materials** Chemical reagents and solvents were purchased either from Sigma-Aldrich and Tokyo Chemical Industry Co., or Acros, and used without further purification. **1** and **4a**–**c** were prepared with previously reported protocols.¹⁶ **General procedure for cross-coupling reactions** To a solution of γ-lactam embedded indolizines (**4a**–**c**) in dimethylformamide, 10 volume% acetic acid, styrene derivatives (3 equiv.), palladium acetate (0.1 equiv.) and silver acetate (2 equiv.) were added and stirred at 80 $\rm{^{\circ}C}$ for overnight (20 h). After the reaction completion as monitored by TLC, reaction mixture was concentrated *in vacuo* after filtration. The residue was purified by silica gel flash

¹H and ¹³C NMR spectra were recorded on Bruker DRX-300 (Bruker Biospin, Germany) and Varian Inova-500 (Varian Assoc, Palo Alto, USA), chemical shifts were measured in ppm downfield from internal

*tert***-Butyl (E)-(3-(7-acetyl-3-oxo-9-styryl-1,3-dihydro-2H-pyrrolo [3,4-***β***]indolizin-2-yl)propyl)carbamate (5).** ¹H NMR (300 MHz, CDCl3) δ 8.49 (d, *J* = 7.2 Hz, 1H), 8.30 (s, 1H), 7.55 (d, *J* = 7.8 Hz, 2H), 7.43-7.32 (m, 4H), 7.25 (d, *J* = 7.2 Hz, 1H), 6.69 (d, *J* = 15.9 Hz, 1H), 5.36 (br s, 1H), 4.57 (s, 2H), 3.73 (t, *J* = 6.0 Hz, 2H), 3.21 (d, *J* $= 5.1$ Hz, 2H), 2.68 (s, 3H), 1.92–1.88 (m, 2H), 1.46 (s, 9H); ¹³C NMR (75 MHz, CDCl3) δ 193.4, 161.7, 156.2, 137.3, 136.0, 133.1, 128.8, 128.7, 128.5, 127.9, 127.5, 126.0, 124.6, 123.4, 120.0, 117.8, 112.0, 109.7, 79.2, 47.2, 40.2, 37.4, 28.8, 28.4, 26.2; HRMS (FAB+) m/z calcd. for $C_{28}H_{31}N_3O_4$ [M]⁺ 473.23; found: 473.2315.

column chromatography to afford the desired product (**5**–**18**).

*tert-***Butyl (E)-(3-(7-acetyl-9-(4-nitrostyryl)-3-oxo-1,3-dihydro-2H-pyrrolo[3,4-***β***]indolizin-2-yl)propyl)carbamate (6).** ¹H NMR (300 MHz, DMSO) δ 8.79 (s, 1H) 8.42 (d, *J* = 7.2 Hz, 1H), 8.21 (d, *J* = 8.7 Hz, 2H), 8.05 (d, *J* = 15.9 Hz, 1H), 7.89 (d, *J* = 8.7 Hz, 2H), 7.24 (d, *J* = 7.2 Hz, 1H), 6.79 (d, *J* = 16.2 Hz, 1H), 4.69 (s, 2H), 3.51 (t, *J* = 6.6 Hz, 2H), 3.01 (dd, *J* = 11.0, 5.0 Hz, 2H), 2.66 (s, 3H), 1.81–1.76

(m, 2H), 1.38 (s, 9H); HRMS (FAB+) m/z calcd. for $C_{28}H_{30}N_4O_6$ [M]⁺ 518.22; found: 518.2165.

*tert***-Butyl (***E***)-(3-(7-acetyl-3-oxo-9-(2-(perfluorophenyl)vinyl)-1,3 dihydro-2***H***-pyrrolo[3,4-***β***]indolizin-2-yl)propyl)carbamate (7).** ¹H NMR (300 MHz, CDCl3) δ 8.56 (d, *J* = 7.2 Hz, 1H), 8.27 (s, 1H), 7.73 (d, *J* = 16.5 Hz, 1H), 7.33 (d, *J* = 7.2 Hz, 1H), 6.51 (d, *J* = 16.5 Hz, 1H), 5.30 (br s, 1H), 4.59 (s, 2H), 3.74 (t, *J* = 6.5 Hz, 2H), 3.21 (dd, *J* = 12.3, 6.0 Hz, 2H), 2.69 (s, 3H), 1.95–1.86 (m, 2H), 1.45 (s, 9H); ¹³C NMR (75 MHz, CDCl3) δ 195.2, 161.4, 156.1, 136.8, 133.6, 129.8, 126.3 (t, ²J_{C,F} = 9.4 Hz), 126.2, 124.9, 124.0, 119.5, 112.6, 112.5, 111.4, 111.38, 111.33, 111.2, 110.2, 79.2, 47.0, 40.3, 37.3, 29.7, 28.8, 28.4, 26.2; HRMS (FAB+) m/z calcd. for $C_{28}H_{26}F_5N_3O_4 [M+H]^+$ 564.19; found: 564.1922.

*tert***-Butyl (***E***)-(3-(7-acetyl-3-oxo-9-(4-(trifluoromethyl)styryl)-1,3 dihydro-2***H***-pyrrolo[3,4-***β***]indolizin-2-yl)propyl)carbamate (8).** ¹H NMR (300 MHz, CDCl3) δ 8.52 (d, *J* = 7.2 Hz, 1H), δ 8.32 (s, 1H), 7.64 (s, 4H), 7.48 (d, *J* = 16.2 Hz, 1H), 7.29 (d, *J* = 7.2 Hz, 1H), 6.69 (d, *J* = 16.2 Hz, 1H), 5.31 (br s, 1H), 4.60 (s, 2H), 3.73 (t, *J* = 6.3 Hz, 2H), 3.21 (dd, *J* = 12.3, 6.0 Hz, 2H), 2.69 (s, 3H), 1.95–1.86 (m, 2H), 1.45 (s, 9H); ¹³C NMR (75 MHz, CDCl3) δ 195.3, 161.5, 156.1, 140.8, 139.8, 136.4, 133.5, 129.2, 129.0 (q, ²J_{C,F} = 31.5 Hz), 126.0, 125.7 (q, ${}^{3}J_{\text{C,F}}$ = 3.8 Hz), 125.7 (q, ¹J_{C,F} = 143 Hz), 123.7, 120.3, 119.6, 111.3, 110.0, 79.2, 47.1, 40.2, 37.4, 29.7, 28.8, 28.4, 26.3; HRMS (FAB+) m/z calcd. for C29H30F3N3O⁴ [M]⁺ 541.22; found: 541.2188.

*tert***-Butyl (***E***)-(3-(7-acetyl-9-(4-bromostyryl)-3-oxo-1,3-dihydro-2***H***-pyrrolo[3,4-***β***]indolizin-2-yl)propyl)carbamate (9).** ¹H NMR (300 MHz, CDCl3) δ 8.52 (d, *J* = 6.6 Hz, 1H), 8.31 (s, 1H), 7.52 (d, *J* = 8.4 Hz, 2H), 7.42 (d, *J* = 7.5 Hz, 2H), 7.36 (s, 1H), 7.27 (s, 1H), 6.62(d, *J* = 15.9 Hz, 1H), 5.32 (br s, 1H), 4.58 (s, 2H), 3.75–3.65 (m, 2H), 3.21 (dd, *J* = 11.4, 5.7 Hz, 2H), 2.69 (s, 3H), 1.92–1.82 (m, 2H), 1.45 (s, 9H); ¹³C NMR (75 MHz, CDCl3) δ 195.3, 161.6, 156.1, 138.0, 136.3, 133.2, 131.9, 128.9, 127.4, 127.1, 124.7, 123.6, 122.1, 121.1, 119.8, 118.6, 111.6, 109.8, 79.2, 47.1, 40.2, 37.4, 29.7, 28.4, 26.3; HRMS (FAB+) m/z calcd. for $C_{28}H_{30}BrN_3O_4$ [M]⁺ 551.14; found: 551.1420.

*tert***-Butyl (***E***)-(3-(7-acetyl-9-(4-methylstyryl)-3-oxo-1,3-dihydro-2***H***-pyrrolo[3,4-***β***]indolizin-2-yl)propyl)carbamate (10).** ¹H NMR (300 MHz, CDCl3) δ 8.46 (d, *J* = 7.8 Hz, 1H), 8.28 (s, 1H), 7.44 (d, *J* $= 7.8$ Hz, 2H), 7.34 (s, 1H), 7.24–7.19 (m, 3H), 6.65 (d, $J = 15.9$ Hz, 1H), 5.36 (br s, 1H), 4.55 (s, 2H), 3.71 (t, *J*= 6.5 Hz, 2H), 3.20 (dd, *J* = 12.2, 6.2 Hz, 2H), 2.66 (s, 3H), 2.39 (s, 3H), 1.93–1.84 (m, 2H), 1.45 (s, 9H); ¹³C NMR (75 MHz, CDCl3) δ 195.4, 161.7, 156.1, 137.5, 135.8, 134.5, 133.0, 129.5, 128.5, 125.9, 124.5, 123.4, 120.0, 116.8, 112.2, 109.6, 79.1, 47.1, 40.2, 37.3, 29.7, 28.8, 28.4, 26.2, 21.3; HRMS (FAB+) m/z calcd. for C29H33N3O⁴ [M]⁺ 487.25; found: 487.2471.

*tert***-Butyl (***E***)-(3-(7-acetyl-9-(4-methoxystyryl)-3-oxo-1,3-dihydro -2***H***-pyrrolo[3,4-***β***]indolizin-2-yl)propyl)carbamate (11).** ¹H NMR (300 MHz, CDCl3) δ 8.48 (d, *J* = 7.2 Hz, 1H), 8.30 (s, 1H), 7.49 (d, *J* = 8.7 Hz, 2H), 7.25 (dd, *J* = 11.7, 5.0 Hz, 2H), 6.95 (d, *J* = 8.7 Hz, 2H), 6.66 (d, *J* = 16.2 Hz, 1H), 5.36 (br s, 1H), 4.57 (s, 2H), 3.87 (s, 3H), 3.72 (t, *J* = 6.3 Hz, 2H), 3.21 (dd, *J*= 12.6, 6.0 Hz, 2H), 2.67 (s,

3H), 1.93–1.87 (m, 2H), 1.45 (s, 9H); ¹³C NMR (75 MHz, CDCl3) δ 195.4, 161.7, 159.3, 156.1, 135.7, 132.8, 130.1, 128.4, 128.3, 127.2, 124.5, 123.3, 120.1, 115.8, 114.3, 112.4, 109.5, 79.1, 55.4, 47.1, 40.2, 37.4, 31.9, 29.7, 28.4, 26.2; HRMS (FAB+) m/z calcd. for C29H33N3O⁵ [M]⁺ 503.24; found: 503.2420.

*tert***-Butyl (***E***)-(3-(7-acetyl-9-(4-aminostyryl)-3-oxo-1,3-dihydro-2***H***-pyrrolo[3,4-***β***]indolizin-2-yl)propyl)carbamate (12).** 4 nitrostyrene was used as a substrate of cross-coupling reaction and reduced by tin(II) chloride dihydrate in dimethylformamide and 10 volume% acetic acid. ¹H NMR (300 MHz, CDCl3) δ 8.43 (d, *J* = 6.9 Hz, 1H), 8.24 (s, 1H), 7.35 (d, *J* = 8.1 Hz, 2H), 7.21–7.12 (m, 2H), 6.72 (d, *J* = 7.8 Hz, 2H), 6.58 (d, *J* = 16.2 Hz, 1H), 5.39 (br s, 1H), 4.51 (s, 2H), 3.70 (t, *J* = 5.9 Hz, 2H), 3.20 (d, *J* = 5.1 Hz, 2H), 2.65 (s, 3H), 1.90–1.86 (m, 2H), 1.46 (s, 9H); ¹³C NMR (75 MHz, CDCl3) δ 195.4, 161.7, 156.1, 146.2, 135.4, 132.6, 128.9, 128.1, 127.9, 127.3, 124.4, 123.2, 120.2, 115.3, 114.2, 112.7, 109.4, 79.1, 47.1, 40.1, 37.3, 29.7, 28.8, 28.4, 26.2; HRMS (FAB+) m/z calcd. for $C_{28}H_{32}N_4O_4$ [M]⁺ 488.24; found: 488.2424.

Methyl (*E***)-9-(4-bromostyryl)-2-(3-((***tert***-butoxycarbonyl)amino) propyl)-3-oxo-2,3-dihydro-1***H***-pyrrolo[3,4-***β***]indolizine-7-**

carboxylate (13). ¹H NMR (500 MHz, CDCl3) δ 8.49 (d, *J* = 7.5 Hz, 1H), 8.43 (s, 1H), 7.50 (d, *J* = 8.5 Hz, 2H), 7.39 (d, *J* = 8.5 Hz, 2H), 7.35 (d, *J* = 16.5 Hz, 1H), 7.27 (d, *J* = 8.5 Hz, 1H), 6.58 (d, *J* = 16.0 Hz, 1H), 5.34 (br s, 1H), 4.55 (s, 2H), 3.98 (s, 3H), 3.71 (t, *J* = 6.5 Hz, 2H), 3.19 (dd, *J* = 11.3, 5.8 Hz, 2H), 1.91–1.86 (m, 2H), 1.44 (s, 9H); ¹³C NMR (75 MHz, CDCl3) δ 165.7, 161.7, 156.2, 136.4, 133.3, 131.9, 127.4, 126.8, 124.6, 123.3, 122.1, 121.0, 118.7, 111.0, 79.3, 52.6, 47.2, 40.3, 37.4, 29.8, 28.8, 28.5; HRMS (FAB+) m/z calcd. for C28H30BrN3O⁵ [M]⁺ 567.14; found: 567.1369.

Methyl (*E***)-2-(3-((***tert***-butoxycarbonyl)amino)propyl)-3-oxo-9 styryl-2,3-dihydro-1***H***-pyrrolo[3,4-***β***]indolizine-7-carboxylate**

(14). ¹H NMR (300 MHz, CDCl3) δ 8.42 (d, *J* = 7.2 Hz, 1H), 8.37 (s, 1H), 7.51 (d, *J* = 7.2 Hz, 2H), 7.41–7.34 (m, 3H), 7.28 (d, *J* = 7.2 Hz, 1H), 7.22 (d, *J* = 7.2 Hz, 1H), 6.61 (d, *J* = 16.2 Hz, 1H), 5.41 (br s, 1H), 4.50 (s, 2H), 3.96 (s, 3H), 3.69 (t, *J* = 6.5 Hz, 2H), 3.20 (br s, 2H), 1.90-1.86 (m, 2H), 1.45 (s, 9H); ¹³C NMR (75 MHz, CDCl3) δ 165.6, 161.7, 156.2, 140.8, 137.3, 136.2, 133.1, 128.8, 128.5, 128.2, 127.7, 127.4, 125.9, 124.3, 123.0, 121.7, 120.9, 117.8, 79.2, 52.4, 47.1, 40.2, 37.4, 31.1, 28.8, 28.4; HRMS (FAB+) m/z calcd. for C28H31N3O⁵ [M]⁺ 489.23; found: 489.2264.

Methyl (*E***)-2-(3-((***tert***-butoxycarbonyl)amino)propyl)-9-(4 methoxystyryl)-3-oxo-2,3-dihydro-1***H***-pyrrolo[3,4-***β***]indolizine-7 carboxylate (15).** ¹H NMR (300 MHz, CDCl3) δ 8.40 (d, *J* = 6.0 Hz, 1H), 8.35 (s, 1H), 7.44 (d, *J* = 7.2 Hz, 2H), 7.20–7.13 (m, 2H), 6.92 $(d, J = 8.4 \text{ Hz}, 2\text{H}), 6.55 \ (d, J = 16.5 \text{ Hz}, 1\text{H}), 5.42 \ (br \text{br s}, 1\text{H}), 4.48 \ (s,$ 2H), 3.95 (s, 3H), 3.85 (s, 3H), 3.68 (t, *J* = 5.0 Hz, 2H), 3.19 (br s, 2H), 1.89-1.85 (m, 2H), 1.44 (s, 9H); ¹³C NMR (75 MHz, CDCl3) δ 165.7, 161.8, 159.2, 156.3, 135.9, 132.8, 130.2, 127.9, 127.2, 124.3, 122.8, 121.4, 121.0, 115.8, 114.2, 111.6, 110.6, 79.3, 55.3, 52.4, 47.1, 40.2, 37.4, 31.1, 28.8, 28.4; HRMS (FAB+) m/z calcd. for C29H33N3O⁶ [M]⁺ 519.24; found: 519.2369.

*tert***-Butyl (***E***)-(3-(9-(4-bromostyryl)-7-methyl-3-oxo-1,3-dihydro-2***H***-pyrrolo[3,4-***β***]indolizin-2-yl)propyl)carbamate (16).** ¹H NMR $(300 \text{ MHz}, \text{CDC1}_3)$ δ 8.42 (d, $J = 6.9 \text{ Hz}, 1\text{ H}$), 7.48 (d, $J = 8.4 \text{ Hz}, 2\text{ H}$), 7.43–7.32 (m, 3H), 7.27 (s, 1H), 6.62 (d, *J* = 6.9 Hz, 1H), 6.47 (d, *J* = 15.9 Hz, 1H), 5.42 (br s, 1H), 4.52 (s, 2H), 3.70 (t, *J* = 6.3 Hz, 2H), 3.20 (t, *J* = 6.0 Hz, 2H), 2.42 (s, 3H), 1.90–1.86 (m, 2H), 1.45 (s, 9H); ¹³C NMR (75 MHz, CDCl3) δ 162.4, 138.7, 137.0, 133.9, 132.8, 131.7, 127.0, 124.9, 124.0, 120.2, 120.1, 119.5, 115.8, 114.9, 105.7, 79.4, 42.3, 40.2, 29.7, 28.9, 28.4, 21.6; HRMS (FAB+) m/z calcd. for C27H30BrN3O³ [M]⁺ 523.15; found: 523.1471.

*tert***-Butyl (***E***)-(3-(7-methyl-3-oxo-9-styryl-1,3-dihydro-2***H***pyrrolo[3,4-***β***]indolizin-2-yl)propyl)carbamate (17).** Copper(II) acetate (2 equiv.) was used as oxidant instead of silver acetate. ¹H NMR (300 MHz, CDCl3) δ 8.42 (d, *J* = 6.9 Hz, 1H), 7.51 (d, *J* = 7.5 Hz, 2H), 7.44–7.34 (m, 4H), 7.25 (d, *J* = 7.2 Hz, 1H), 6.61-6.53 (m, 2H), 5.48 (br s, 1H), 4.53 (s, 2H), 3.70 (t, *J* = 6.5 Hz, 2H), 3.20 (t, *J*= 5.4 Hz, 2H), 2.42 (s, 3H), 1.90-1.86 (m, 2H), 1.46 (s, 9H); HRMS (FAB+) m/z calcd. for C27H31N3O³ [M]⁺ 445.24; found: 445.2365.

*tert***-Butyl (***E***)-(3-(9-(4-methoxystyryl)-7-methyl-3-oxo-1,3 dihydro-2***H***-pyrrolo[3,4-***β***]indolizin-2-yl)propyl)carbamate (18).** ¹H NMR (300 MHz, CD3OD) δ 8.36 (d, *J* = 6.9 Hz, 1H), 7.56 (s, 1H), 7.48 (d, *J* = 8.7 Hz, 2H), 7.25 (d, *J* = 16.2 Hz, 1H), 6.91 (d, *J* = 8.7 Hz, 2H), 6.66 (d, *J* = 6.9 Hz, 1H), 6.58 (d, *J* = 16.2 Hz, 1H), 5.35 (br s, 1H), 4.58 (s, 2H), 3.82 (s, 3H), 3.65 (t, *J* = 8.4 Hz, 2H), 3.14 (t, *J* = 6.8 Hz, 2H), 2.40 (s, 3H), 1.91-1.87 (m, 2H), 1.43 (s, 9H); HRMS (FAB+) m/z calcd. for C28H33N3O⁴ [M]⁺ 475.25; found: 475.2471.

Preparation of *tert***-butyl (3-(7-acetyl-3-oxo-9-(perfluorophenyl)- 1,3-dihydro-2***H***-pyrrolo[3,4-***β***]indolizin-2-yl)propyl)carbamate.**

tert-Butyl (3-(7-acetyl-3-oxo-9-(perfluorophenyl)-1,3-dihydro-2*H*pyrrolo[3,4-*b*]indolizin-2-yl)propyl)carbamate was synthesized by previously reported method.¹⁶

*tert***-Butyl (3-(7-acetyl-3-oxo-9-(perfluorophenyl)-1,3-dihydro-2***H***-pyrrolo[3,4-***β***]indolizin-2-yl)propyl)carbamate.** ¹H NMR (300 MHz, CDCl3) δ 8.68 (d, *J* = 7.2 Hz, 1H), 7.99 (s, 1H), 7.43 (d, *J* = 7.2 Hz, 1H), 5.30 (br s, 1H), 4.40 (s, 2H), 3.70 (t, *J* = 6.3 Hz, 2H), 3.20 (dd, *J*= 12.3, 6.3 Hz, 2H), 2.65 (s, 3H), 1.88–1.83 (m, 2H), 1.45 (s, 9H); HRMS (FAB+) m/z calcd. for $C_{26}H_{24}F_5N_3O_4$ [M+H]⁺ 538.18; found: 538.1765.

Acknowledgements

This work was supported by the National Creative Research Initiative Grant (2014R1A3A2030423) and Bio & Medical Technology Development Program (2012M3A9C4048780) through the National Research Foundation of Korea (NRF) funded by the Korean Government (Ministry of Science, ICT & Future Planning).

Notes and references

^a Department of Chemistry, Seoul National University, Seoul 151-747, Korea.

^b WCU Department of Biophysics and chemical Biology/N-Bio institute, Seoul National University, Seoul 151-747 Korea.

E-mail: [sbpark@snu.ac.kr;](mailto:sbpark@snu.ac.kr) Fax: +82 2 884 4025; Tel: +82 2 880 9090

† Electronic Supplementary Information (ESI) available: Additional figures, full characterization and spectroscopic data of all new compounds, and detailed experimental protocols. See DOI: 10.1039/ c000000x/

- 1 J. R. Lakowicz, *Principles of Fluorescence Spectroscopy*, Springer-Verlag, New York, 3rd edn., 2006; W. Rettig, B. Strehmel, S. Schrader, and H. Seifert, Eds., *Applied Fluorescence in Chemistry, Biology, and Medicine*, Springer, New York, 1999; J. J. Lavigne and E. V. Anslyn, *Angew. Chem. Int. Ed.*, 2011, **40**, 3118; J. Zhang, R. E. Campbell, A. Y. Ting, and R. Y. Tsien, *Nat. Rev. Mol. Cel. Biol.*, 2002, **3**, 906; D. W. Domaille, E. L. Que, and C. J. Chang, *Nat. Chem. Biol.*, 2008, **4**, 168.
- 2 R. P. Haugland, *Handbook of Fluorescence Probes and Research Products*, Molecular Probes: Eugene, OR, 10th edn.
- 3 A. Burghart, H. J. Kim, M. B. Welch, L. H. Thoresen, J. Reibenspies, K. Burgess, F. Bergstrom and L. B. A. Johansson, *J. Org. Chem.*, 1999, **64**, 7813; K. Yamada, T. Toyota, K. Takakura, M. Ishimaru and T. Sugawara, *New J. Chem.*, 2001, **25**, 667.
- 4 W. L. Zhao and E. M. Carreira, *Angew. Chem.*, 2005, **117**, 1705; W. L. Zhao and E. M. Carreira, *Chem. Eur. J.*, 2006, **12**, 7254; J. Chen, A. Burghart, A. Derecskei-Kovacs and K. Burgess, *J. Org. Chem.*, 2000, **65**, 2900.
- 5 J. Killoran, L. Allen, J. F. Gallagher, W. M. Gallagher and D. F. O'Shea, *Chem. Commun.*, 2002, **17**, 1862; A. Gorman, J. Killoran, C. O'Shea, T. Kenna, W. M. Gallagher and D. F. O'Shea, *J. Am. Chem. Soc.*, 2004, **126**, 10619; M. Fu, Y. Xiao, X. Qian, D. Zhao and Y. Xu, *Chem. Commun.*, 2008, **15**, 1780; Y. Koide, Y. Urano, K. Hanaoka, T. Terai and T. Nagano, *ACS Chem. Biol.*, 2011, **6**, 600.
- 6 K. Rurack, M. Kollmannsberger and J. Daub, *Angew. Chem.*, 2001, **113**, 396; K. Rurack, M. Kollmannsberger and J. Daub, *Angew. Chem. Int. Ed.*, 2001, **40**, 385; S. Atilgan, Z. Ekmekci, A. L. Dogan, D. Guc and E. U. Akkaya, *Chem. Commun.*, 2006, **42**, 4398.
- 7 Z. Shen, H. Rohr, K. Rurack, H. Uno, M. Spieles, B. Schulz, G. Reck and N. Ono, *Chem. Eur. J.*, 2004, **10**, 4853; S. Goeb and R. Ziessel. *Org. Lett.*, 2007, **9**, 737; M. Wada, S. Ito, H. Uno, T. Murashima, N. Ono, T. Urano and Y. Urano, *Tetrahedron Lett.*, 2001, **42**, 6711; K. Umezawa, Y. Nakamura, H. Makino, D. Citterio and K. Suzuki, *J. Am. Chem. Soc.*, 2008, **130**, 1550; K. Umezawa, A. Matsui, Y. Nakamura, D. Citterio and K. Suzuki, *Chem. Eur. J.*, 2009, **15**, 1096.
- 8 R. B. Mujumdar, L. A. Ernst, S. R. Mujumdar, C. J. Lewis and A. S. Waggoner, *Bioconjugate Chem.*, 1993, **4**, 105; S. H. Kim, G. Park, H. Hyun, J. H. Lee, Y. Ashitate, J. Choi, G. H Hong, E. A Owens, M. Henary and H. S. Choi, *Biomed. Mater.*, 2013, **8**, 014110; E. A Owens, H. Hyun, S. H. Kim, J. H. Lee, G. Park, Y. Ashitate, J. Choi, G. H Hong, S. Alyabyev, S. J. Lee, G. Khang, M. Henary and H. S. Choi, *Biomed. Mater.*, 2013, **8**, 014109.
- 9 V. Leen, T. Leemans, N. Boens and W. Dehaen, *Eur. J. Org. Chem.*, 2011, **23**, 4386.
- 10 K. Hara, K. Sayama, Y. Ohga, A. Shinpo, S. Suga and H. Arakawa, *Chem. Commun.*, 2001, **6**, 569.
- 11 E. Kim, M. Koh, J. Ryu and S. B. Park, *J. Am. Chem. Soc.*, 2008, **130**, 12206.
- 12 E. Kim, M. Koh, B. J. Lim and S. B. Park, *J. Am. Chem. Soc.*, 2011, **133**, 6642.
- 13 E. Kim, S. Lee and S. B. Park, *Chem. Commun.*, 2011, **47**, 7734.
- 14 M. S. Jeong, E. Kim, H. J. Kang, E. J. Choi, A. R. Cho, S. J. Chung and S. B. Park, *Chem. Commun.*, 2012, **48**, 6553.
- 15 E. Kim, S. Lee and S. B. Park, *Chem. Commun.*, 2012, **48**, 2331; Y. Lee, S. Na, S. Lee, N. L. Jeon and S. B. Park, *Mol. BioSyst.*, 2013, **9**, 952; S. Lee, E. Kim and S. B. Park, *Chem. Sci.*, 2013, **4**, 3282.
- 16 E. J. Choi, E. Kim, Y. Lee, A. Jo and S. B. Park, *Angew. Chem. Int. Ed.*, 2014, **53**, 1346.
- 17 E. Kim, Y. Lee, S. Lee and S. B. Park, *Acc. Chem. Res.* 2015, **48**, 538.
- 18 S. Su and J. A. Porco, Jr, *J. Am. Chem. Soc.*, 2007, **129**, 7744; C. Najera and J. M. Sansano, *J. Organomet. Chem.*, 2014, **771**, 78.
- 19 D. Garcia-Cuadrado, A. A. C. Braga, F. Maseras and A. M. Echavarren, *J. Am. Chem. Soc.*, 2006, **128**, 1066; S. I. Gorelsky, D. Lapointe and K. Fagnou, *J. Am. Chem. Soc.*, 2008, **130**, 10848; L. Ackermann, *Chem. Rev.*, 2011, **111**, 1315; S. H. Cho, J. Y. Kim, J. Kwak and S. Chang, *Chem. Soc., Rev.*, 2011, **40**, 5068.
- 20 C. Hansch, A. Leo and R. W. Taft, *Chem. Rev.*, 1991, **91**, 165.